Brief: Unicycive Therapeutics Announces FDA Acceptance Of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
29/01/2026 12:30
Jan 29 (Reuters) - Unicycive Therapeutics Inc UNCY.O: UNICYCIVE THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF OXYLANTHANUM CARBONATE (OLC) NEW DRUG APPLICATION (NDA) RESUBMISSION UNICYCIVE THERAPEUTICS INC - PDUFA TARGET ACTION DATE SET FOR JUNE 27, 2026 Source text: ID:nGNX1cqGlB Further company coverage: UNCY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss